Individuals with HIV receive greater protection against the flu when given four times the normal dose of flu vaccine, a new study shows.
Emergent BioSolutions snagged the exclusive right to manufacture and sell VaxInnate's flu vaccine, a product Emergent can produce quickly at high yields and low cost.
A universal influenza vaccine is the virtual Holy Grail for flu scientists, and a researcher and his collaborators at Georgia State University's Center for Inflammation, Immunity and Infection moved a step closer to developing the elusive shot.
The FDA gave the OK to GlaxoSmithKline's new four-strain seasonal flu vaccine, which the company said will become available for the 2013-2014 flu season.
An early flu season is under way, the national Centers for Disease Control and Prevention reports, and will likely prove formidable.
One way to start up a vaccine manufacturing operation is to simply take over a mothballed plant left idle by one of Big Pharma's merger shakeouts. That is exactly what Protein Sciences is doing in New York.
The lease gives Meriden, CT-based Protein Sciences access to 83,000 square feet of space at Pfizer's 550-acre Pearl River campus, which has been subject to cutbacks within the past couple of years.
When it comes to flu pandemics, making and distributing vaccines quickly is of utmost importance. And now German scientists have developed an RNA vaccine that could cut flu vaccine production time from months to weeks.
Novartis will use a process to manufacture its seasonal flu vaccine at its new plant in Holly Springs, NC, that is based on animal cell cultures and so will cut weeks off production times.
The FDA approved Novartis' novel flu vaccine produced using cultured animal cells instead of the traditional manufacturing process that uses fertilized chicken eggs.